Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your #1 Sort of Convenience for a Family - 2SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- 3Coffee Prices Finish Higher on Brazil Cop Concerns
- 4Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- 5Vote in favor of the wide open action that revives your brain and soul!
- Germany and trade unions kick off tough public-sector wage talks
- 6 Exercises to Anticipate in 2024
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine
- Pick Your Favored method of transportation
- Opening Achievement: 8 Methodologies for Compelling Using time productively
- NASA study shows how satellite 'light pollution' hinders space telescopes
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
